Exploring Drug Repositioning: Enhanced Co-Delivery of Disulfiram andCelecoxib by Nanostructured Lipid Carriers for Breast Cancer Cells
These results suggest that repurposing DSF and CXB NLCs holds promise as a co-delivery system for various cancers, potentially leading to improved therapeutic outcomes.
Authors
- Sana Ghayas
- Perpetua Takunda Kutoka (ORCID: https://orcid.org/0000-0002-0602-923X)
- Raphael N. Alolga
- Muhammad Asim Farooq (ORCID: https://orcid.org/0000-0002-4569-2317)
- Theodora Amanda Seidu (ORCID: https://orcid.org/0000-0003-2083-9308)
- Bo Wang (ORCID: https://orcid.org/0000-0002-7547-0088)
- Masanja Pius Wande
Institutions
- Muhimbili University of Health and Allied Sciences (TZ)
- China Pharmaceutical University (CN)
- Dow University of Health Sciences (PK)
- Monash University (AU)
Publication Details
- Journal
- Current Drug Delivery
- Published
- 2025-08-12
- DOI
- https://doi.org/10.2174/0115672018287555240426063812
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00